- SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target.
- The analyst believes the company's potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity.
- It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted).
- The outlook is supported by the pediatric rotavirus vaccine analog (2021 global sales of Rotateq and Rotarix combined were $1.6 billion).
- The company also plans to study HIL214 in older adults, which could represent a second blockbuster indication.
- SVB also noted that HLVX shares had traded down -41% post IPO vs. -5% for the XBI, likely due to market dislocation.
- It believes this provides an attractive entry point for investors as HLVX's $380 million market cap appears heavily discounted vs. its $1.2 billion discounted cash flow-based valuation.
- SVB expects infant Phase 2b safety data in 2H22, immunogenicity data in 1H23, and top-line efficacy data in 2H23.
- Concurrently, Guggenheim initiated coverage on HilleVax with a Buy rating and a price target of $40. JP Morgan initiated coverage on HilleVax with an Overweight rating and a price target of $24.
- Price Action: HLVX shares are up 8.68% at $10.33 during the market session on the last check Tuesday.
SVB Sees De-Risked Opportunity For This This Newly Listed Norovirus Vaccine
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.